In vitro procoagulant effects of Gla-domainless factor Xa in factor XI-deficient and factor IX-deficient plasma.

COI Statement

Declaration of competing interest AB has received research support from Cellphire Therapeutics, HemoSonics, Hikari DX and Octapharma; KT has received research support from Cellphire Therapeutics, Hikari DX and Octapharma, and participated in an advisory meeting for Werfen; MM has received consulting fees from Octapharma, HemoSonics, and NovoNordisk; other report no conflict of interest.